

Table1 Characteristics of EU patients for IN1602

Variable	MBI-LCBI and other BSI N(%)	MBI-LCBI only N(%)	BSI only N(%)	Control N(%)
Number of patients	16	28	52	229
Disease				
AML	9 (56)	6 (21)	14 (27)	88 (38)
ALL	2 (13)	7 (25)	11 (21)	25 (11)
MDS	1 (6)	6 (21)	11 (21)	66 (29)
Severe aplastic anemia	1 (6)	3 (11)	1 (2)	17 (7)
Inherited abnormalities erythrocyte differentiation or function	1 (6)	3 (11)	5 (10)	21 (9)
SCID and other immune system disorders	1 (6)	2 (7)	1 (2)	5 (2)
Inherited disorders of metabolism	0	1 (4)	5 (10)	4 (2)
Histiocytic disorders	1 (6)	0	4 (8)	3 (1)
Donor/recipient HLA match				
Cord blood	4 (25)	12 (43)	14 (27)	35 (15)
HLA-identical siblings	2 (13)	7 (25)	5 (10)	64 (28)
matched related	0	0	1 (2)	2 (<1)
Mismatched related, mismatch>=2	1 (6)	1 (4)	2 (4)	4 (2)
Mismatched related, mismatch missing	2 (13)	2 (7)	1 (2)	4 (2)
8/8 unrelated	5 (31)	2 (7)	19 (37)	77 (34)
7/8 unrelated	2 (13)	0	7 (13)	18 (8)
<=6/8 unrelated	0	0	0	2 (<1)
Unrelated (HLA match information missing)	0	4 (14)	3 (6)	23 (10)
Conditioning regimen intensity				
MAC+TBI	3 (19)	8 (29)	11 (21)	35 (15)
MAC no TBI	4 (25)	5 (18)	7 (13)	40 (17)
RIC/NMA + TBI	2 (13)	2 (7)	5 (10)	51 (22)
RIC/NMA no TBI	3 (19)	4 (14)	13 (25)	53 (23)
Non Malignancies + TBI	0	0	0	7 (3)
Non Malignancies no TBI	4 (25)	9 (32)	16 (31)	43 (19)
GVHD prophylaxis				
Ex vivo T-cell depletion	0	0	0	1 (<1)
CD34 selection	0	0	0	1 (<1)
Cyclophosphamide	4 (25)	3 (11)	4 (8)	6 (3)
TAC/CSA + MMF +/- others	4 (25)	8 (29)	20 (38)	76 (33)
TAC/CSA + MTX +/- others	7 (44)	5 (18)	15 (29)	94 (41)
TAC/CSA + others (except MTX, MMF)	1 (6)	9 (32)	8 (15)	12 (5)
TAC/CSA alone	0	2 (7)	4 (8)	32 (14)
MMF +/- Other	0	0	1 (2)	0
SIRO +/- others (Not TAC/CSA)	0	1 (4)	0	5 (2)
Steroids alone	0	0	0	1 (<1)
Other GVHD prophylaxis	0	0	0	1 (<1)

